JBL Your CRDMO Partner in Science
JA
EN
  • About Us
    • Vision, Values & Promise
    • Company Overview
    • Leadership Team
    • Our Facilities
    • Contact Us
  • Services
    • Integrated Drug Discovery
      • Target Identification
      • Target Validation
      • HIT Identification
      • HIT to Lead
      • Lead Optimization
      • Candidate Selection
    • Chemistry
      • Synthetic Chemistry
      • Medicinal Chemistry
      • Analytical Chemistry
      • Computational Chemistry
      • Specialised Chemistry-COE
      • Oligonucleotide Offerings
    • Protein Sciences and Crystallography
      • Custom Protein Production
      • SPR
      • Crystallography
      • SBDD
    • Assay Biology
      • In-Vitro Biology
      • Target Validation
      • Bio-Chemical Assay, D&S
      • Cell Based Assay, D&S
      • Mode of Action Studies
      • Biomarker Evaluation
    • DMPK
      • Physicochemical Properties
      • In-Vitro ADME
      • In-Vivo Pharmacokinetics
      • Drug Interactions
      • Metabolite Identification
      • Bioanalysis
      • Large Molecule Bioanalysis
    • Computational Chemistry (CADD)
      • Virtual Screening
      • LBDD
      • Insilico FBDD
      • Chemoinformatics
    • Pharmacology
      • Oncology Animal Models
      • Inflammation Animal Models
      • Pain and Neuroscience Animal Models
      • Diabetes & Metabolic Disorders Animal Models
    • Toxicology
      • GLP & Non GLP Studies
      • Acute Toxicity
      • Subchronic Toxicity
      • Genetic Toxicity
      • Safety Pharmacology
      • Toxicokinetics
    • CDMO
      • Process R&D Services
      • Analytical Development
      • Process Safety Studies
      • Polystate Capabilities
      • Technology Transfer
      • Early to Late Phase Supplies
      • GLP, Non-GMP and GMP Mfg.
    • Biologics
      • Recombinant Protein Production
      • ADC Capabilities
      • API
        • API Capabilities
    • For more information reach us at: bd@jubilantbiosys.com
  • Target Approaches
    • Kinases
    • Non-Kinase Enzymes
    • GPCRs & Ion Channels
    • Transcription Factors
    • Immune Regulators
    • Target Protein Degradation
    • RNA Small Molecule Drugs
  • Our Commitment
    • EHS
    • Corporate Governance
    • Corporate Social Responsibility
    • Sustainability
    • Quality & IP
    • Policies
  • Resources
    • News
    • Press Releases
    • Events
    • Publications
    • Whitepapers
    • Brochures
    • Webinars
    • Customer Testimonials
    • Annual Return
  • Careers
    • Job Opportunities
    • Job Opportunities in France
    • Returning Indian Talent
    • Recruitment Fraud Advisory
    • Group Ombudsperson

Author: ddAdmin

PTC-174, a positive allosteric modulator of NMDA receptors containing GluN2C or GluN2D subunits

Posted on June 16, 2020March 18, 2025 by ddAdmin
PTC-174, a positive allosteric modulator of NMDA receptors containing GluN2C or GluN2D subunits

Authors: Feng Yi, Nirvan Rouzbeh, Kasper B. Hansen, Yuelian Xu, Christopher M. Fanger, Earl Gordon, Kathy Paschetto, Frank S. Menniti,∗, Robert A. Volkmann

Posted in Publications

Jubilant Life Sciences grants an exclusive license to Lengo Therapeutics to Discover and Develop Oncology Medicines

Posted on May 13, 2020March 18, 2025 by ddAdmin
Jubilant Life Sciences grants an exclusive license to Lengo Therapeutics to Discover and Develop Oncology Medicines

“Company formation is one of our core activities at Frazier, and Jubilant has been a key part of several of our early-stage companies” Daniel Estes, Ph.D., General Partner on the Frazier Life Sciences team.

Posted in Press Releases

Need an Inspired Chemistry Team to Work on your Business?

Posted on March 18, 2020March 18, 2025 by ddAdmin
Need an Inspired Chemistry Team to Work on your Business?
Posted in Whitepapers

Modulating inhibitory response control through potentiation of GluN2D subunit-containing NMDA receptors

Posted on March 2, 2020March 18, 2025 by ddAdmin
Modulating inhibitory response control through potentiation of GluN2D subunit-containing NMDA receptors

Authors: Patrick M. Callahan, Alvin V. Terry Jr., Frederick R. Nelson, Robert A. Volkmann, A.B. Vinod, Mohd Zainuddin, Frank S. Menniti

Posted in Publications

Incurred sample reanalysis of cefuroxime in rabbit ocular tissues – A case study

Posted on January 28, 2020March 18, 2025 by ddAdmin
Incurred sample reanalysis of cefuroxime in rabbit ocular tissues – A case study

Authors: Bhavesh Babulal Gabani, Vinay Kiran, Shuvranshu Praharaj, Nuggehally R. Srinivas, Ramesh Mullangi

Posted in Publications

Stereoselective pharmacokinetics and tissue distribution of levodropropizine after administration of pure levodropropizine and the rac-dropropizine to Sprague–Dawley rats

Posted on January 23, 2020March 18, 2025 by ddAdmin
Stereoselective pharmacokinetics and tissue distribution of levodropropizine after administration of pure levodropropizine and the rac-dropropizine to Sprague–Dawley rats

Authors: Bhavesh Babulal Gabani, Umesh Todmal, Neeraj Kumar Saini, Vinod A. Balakrishna, Suresh P. Sulochana, Ashok Timmapuram, Mohd Zainuddin, Narayanan Balaji, Praharaj Shuvranshu, Nuggehally R. Srinivas & Ramesh Mullangi

Posted in Publications

Uptake and pharmacokinetics of cefuroxime in rabbits after intravitreal, intracameral, and topical dosing: relevance to human ocular injection of cefuroxime

Posted on January 23, 2020March 18, 2025 by ddAdmin
Uptake and pharmacokinetics of cefuroxime in rabbits after intravitreal, intracameral, and topical dosing: relevance to human ocular injection of cefuroxime

Authors: Ravi Kumar Jairam, Sadanand R. Mallurwar, Bhavesh B. Gabani, Ashok Zakkula, Vinay Kiran, Sreekanth Dittakavi, Suresh P. Sulochana, Zainuddin Mohd, Nuggehally R. Srinivas and Ramesh Mullangi

Posted in Publications

Jubilant Biosys Commences Major Capacity Expansions For Its Drug Discovery Services Business

Posted on November 28, 2019March 18, 2025 by ddAdmin
Jubilant Biosys Commences Major Capacity Expansions For Its Drug Discovery Services Business

Due to growing customer demand for its range of functional and integrated drug discovery services, Jubilant Biosys has started the design and construction of a brand new state-of-the-art chemistry services laboratories on the existing Jubilant Greater Noida site.

Posted in Press Releases

White Paper: AI ML Pilot Studies on Drug Repositioning and Drug Target Identification

Posted on October 17, 2019March 18, 2025 by ddAdmin
White Paper: AI ML Pilot Studies on Drug Repositioning and Drug Target Identification

Authors: J.Sooriya Kumar, Maharnob Sarkar, Parimala S Devi

Posted in Publications

High-Affinity Alkynyl Bisubstrate Inhibitors of Nicotinamide N-Methyltransferase (NNMT)

Posted on October 9, 2019March 18, 2025 by ddAdmin
High-Affinity Alkynyl Bisubstrate Inhibitors of Nicotinamide N-Methyltransferase (NNMT)

Authors: Rocco L. Policarpo, Ludovic Decultot, Elizabeth May, Petr Kuzmic, Samuel Carlson, Danny Huang, Vincent Chu, Brandon A. Wright, Saravanakumar Dhakshinamoorthy, Aimo Kannt, Shilpa Rani, Sreekanth Dittakavi, Joseph D. Panarese, Rachelle Gaudet and Matthew D. Shair

Posted in Publications

Posts navigation

Older posts
Newer posts

Get in touch

For Business Queries
bd@jubilantbiosys.com
For Career Related Queries
careers@jubilantbiosys.com

Services

  • Integrated Drug Discovery
  • Chemistry
  • Structural Biology
  • Assay Biology
  • DMPK
  • Computational Chemistry (CADD)
  • Pharmacology
  • Toxicology
  • CDMO

Our Locations

    R&D Centers
  • Noida, India
  • Greater Noida, India
  • Bengaluru, India
  • Saint Julien, France
Manufacturing Plant
  • Nanjangud, India

Company

  • Facilities
  • Contact
  • Careers
  • News

© 2026 Jubilant Biosys Limited A Jubilant Pharmova Limited Company

  • Policies
  • Jubilant Bhartia Group
  • Sitemap
  • Disclaimer
  • Payment

Request For Information

We appreciate all business enquiries, If you'd like our Business Development team to contact you, please complete this form.

    We use cookies to recognize your repeat visits and preferences, as well as to measure the effectiveness of campaigns and analyse traffic. If you continue to use this site, we will assume your acceptance.

    PRIVACY POLICY